Epiheart
Home
Team
Positions
Contact
  • Home
  • Team
  • Positions
  • Contact
Epiheart
Home
Team
Positions
Contact
  • Home
  • Team
  • Positions
  • Contact
  • Home
  • Team
  • Positions
  • Contact

EpiHeart is a young medical device company dedicated to enable surgical administration of novel cellular and gene therapies. Our first focus is Cardiac Micrograft Therapy, a novel autologous cellular therapy administered during CABG surgery to treat ischemic cardiac scars and heart failure.

Seed funding round finalised

EpiHeart raised more than 200 % of the equity funding target in the funding campaign organised on Invesdor platform.


See details
image1

Our Focus

Our Background

Our Background

EpiHeart is dedicated to enable new treatments that improve long term survival and quality of life of cardiac patients.  Our initial focus is in Cardiac Micrograft Therapy(TM). During  Cardiac Artery Bypass Grafting (CABG) surgery patient's own cardiac tissue is processed into micrografts, cleaned and transplanted back to support cardiac tissue regeneration. The pre-clinical and clinical results indicate positive effects on ventricular wall structure and scar size - critical factors contributing to heart failure. 




image2

Our Background

Our Background

Our Background

EpiHeart is a University spin-off company leveraging over 10 years of dedicated research conducted on three continents. Our home is Helsinki, Finland, where we continue  collaboration with University of Helsinki, Helsinki University Hospital "HUS" and Aalto University. 





image3

Collaboration

Our Background

Collaboration

EpiHeart is open for collaboration. We foresee collaboration possibilites in following areas:

  • Clinical studies with European and US clinics performing CABG surgeries. 
  • Distributors able to serve and interact clinics performing CABG surgeries.
  • Research and commercial collaboration relating advanced therapies (cell and gene therapies) that could be administered surgically   

Feel free to request further information on our science, clinical trial program and more.

Follow EpiHeart in social media

Copyright © 2021 Epiheart – Kaikki oikeudet pidätetään.

  • Team
  • Positions
  • Contact
  • Privacy Policy

Powered by GoDaddy Website Builder